{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:07:00Z","timestamp":1793196420792,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:36:00Z","timestamp":1744904160000},"page":"1653-1672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Outcomes of Focal Therapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies"],"prefix":"10.1016","volume":"8","author":[{"given":"Aleksander","family":"\u015alusarczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gurwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Barna\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Zapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"Przydacz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Antczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"\u017byczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Nyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Ma\u0142kiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Drewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Sosnowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.02.003_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2021.07.025","article-title":"Functional and oncological outcomes after open versus robot-assisted laparoscopic radical prostatectomy for localised prostate cancer: 8-year follow-up","volume":"80","author":"Lantz","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41391-022-00520-x","article-title":"Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis","volume":"26","author":"David","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.02.003_b0020","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.02.003_b0025","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.02.003_b0030","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1200\/JCO.2015.65.7759","article-title":"Active surveillance for the management of localized prostate cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement","volume":"34","author":"Chen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0035","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41391-023-00702-1","article-title":"The state of focal therapy in the treatment of prostate cancer: the University of California collaborative (UC-Squared) consensus statement","volume":"27","author":"Javier-DesLoges","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.02.003_b0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00345-024-04840-6","article-title":"High-intensity focused ultrasound with visually directed power adjustment for focal treatment of localized prostate cancer: systematic review and meta-analysis","volume":"42","author":"Peretsman","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10147-020-01847-y","article-title":"Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis","volume":"26","author":"Guo","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0055","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7157973","article-title":"High-intensity focused ultrasound (HIFU) focal therapy for localized prostate cancer with MRI-US fusion platform","volume":"2021","author":"Yee","year":"2021","journal-title":"Adv Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0060","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2018.05.121","article-title":"Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness","volume":"200","author":"Gill","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/JU.0000000000003051","article-title":"A multicenter, randomized, single-blind, 2-arm intervention study evaluating the adverse events and quality of life after irreversible electroporation for the ablation of localized low-intermediate risk prostate cancer","volume":"209","author":"De La Rosette","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0070","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/JU.0000000000001567","article-title":"Prostate Radiofrequency Focal Ablation (ProRAFT) trial: a prospective development study evaluating a bipolar radiofrequency device to treat prostate cancer","volume":"205","author":"Orczyk","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0075","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ijrobp.2019.03.032","article-title":"MRI-guided ultrafocal HDR brachytherapy for localized prostate cancer: median 4-year results of a feasibility study","volume":"104","author":"Peters","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.02.003_b0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2016.09.039","article-title":"Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients","volume":"71","author":"Rischmann","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0085","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.acuro.2018.02.009","article-title":"Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study","volume":"42","author":"Rodriguez-Rivera","year":"2018","journal-title":"Acta Urol Esp (Eng Ed)"},{"key":"10.1016\/j.euo.2025.02.003_b0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bju.15946","article-title":"Median 5\u2010year outcomes of primary focal irreversible electroporation for localised prostate cancer","volume":"131","author":"Scheltema","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.02.003_b0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eururo.2018.12.030","article-title":"Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry","volume":"76","author":"Shah","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0100","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s10147-020-01723-9","volume":"25","author":"Shoji","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/pros.24517","article-title":"Patient\u2010reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: a phase II mandatory biopsy\u2010monitored study","volume":"83","author":"Tan","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.02.003_b0110","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.juro.2016.05.113","article-title":"Final results of a phase I\/II multicenter trial of WST11 vascular targeted photodynamic therapy for hemi-ablation of the prostate in men with unilateral low risk prostate cancer performed in the United States","volume":"196","author":"Taneja","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0115","doi-asserted-by":"crossref","first-page":"150.e1","DOI":"10.1016\/j.urolonc.2016.11.008","article-title":"Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: a prospective development study","volume":"35","author":"Valerio","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/pcan.2015.55","article-title":"A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer","volume":"19","author":"Van Velthoven","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.02.003_b0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jvir.2018.09.016","article-title":"Focal laser ablation of prostate cancer: results in 120 patients with low- to intermediate-risk disease","volume":"30","author":"Walser","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.euo.2025.02.003_b0130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamasurg.2022.2230","article-title":"Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation: a nonrandomized controlled trial","volume":"157","author":"Wang","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.euo.2025.02.003_b0135","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.euf.2022.10.006","article-title":"Medium-term oncological efficacy and patient-reported outcomes after focal high-intensity focused ultrasound: the FOXPRO trial","volume":"9","author":"Westhoff","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.02.003_b0140","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/JU.0000000000003569","article-title":"Biopsy assessment of oncologic control 3 years following primary partial gland cryoablation: a prospective cohort study of men with intermediate-risk prostate cancer","volume":"210","author":"Wysock","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/JU.0000000000002970","article-title":"Focal therapy of prostate cancer index lesion with irreversible electroporation. A prospective study with a median follow-up of 3 years","volume":"209","author":"L\u00f3pez","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0150","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.euf.2021.04.008","article-title":"Long-term outcomes of focal cryotherapy for low- to intermediate-risk prostate cancer: results and matched pair analysis with active surveillance","volume":"8","author":"Marra","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.02.003_b0155","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.juro.2016.02.2986","article-title":"Pilot study to assess safety and clinical outcomes of irreversible electroporation for partial gland ablation in men with prostate cancer","volume":"196","author":"Murray","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0160","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/JU.0000000000001015","article-title":"Prospective evaluation of focal high intensity focused ultrasound for localized prostate cancer","volume":"204","author":"Nahar","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0165","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.euf.2018.04.003","article-title":"Medium-term follow-up of vascular-targeted photodynamic therapy of localized prostate cancer using TOOKAD soluble WST-11 (phase II trials)","volume":"5","author":"Noweski","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.02.003_b0170","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/JU.0000000000000298","article-title":"Extensive histological sampling following focal therapy of clinically significant prostate cancer with high intensity focused ultrasound","volume":"202","author":"Mortezavi","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0175","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.juro.2016.07.074","article-title":"Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer","volume":"196","author":"Eggener","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0180","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S1470-2045(22)00251-0","article-title":"MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study","volume":"23","author":"Ehdaie","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0185","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.urology.2007.07.036","article-title":"Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: initial results","volume":"70","author":"Ellis","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.02.003_b0190","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2015.06.018","article-title":"Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes","volume":"69","author":"Feijoo","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0195","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.3390\/cancers14122988","article-title":"mpMRI-US fusion-guided targeted cryotherapy in patients with primary localized prostate cancer: a prospective analysis of oncological and functional outcomes","volume":"14","author":"Fern\u00e1ndez-Pascual","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.02.003_b0200","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.juro.2017.10.033","article-title":"Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound","volume":"199","author":"Ganzer","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0205","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1148\/radiol.2021202717","article-title":"MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer: early results of a phase II trial","volume":"298","author":"Ghai","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2025.02.003_b0210","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ijrobp.2018.01.066","article-title":"IDEAL 2a phase II study of ultrafocal brachytherapy for low- and intermediate-risk prostate cancer","volume":"102","author":"Graff","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.02.003_b0215","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s00345-020-03575-4","article-title":"Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes","volume":"39","author":"Gregg","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0220","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1007\/s00432-022-04491-3","article-title":"Feasibility of MRI targeted single fraction HDR brachytherapy for localized prostate carcinoma: ProFocAL-study","volume":"149","author":"Hass","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0225","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.urology.2019.06.043","article-title":"Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-center in the United Kingdom","volume":"133","author":"Johnston","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.02.003_b0230","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bju.14948","article-title":"Hemi\u2010ablative low\u2010dose\u2010rate prostate brachytherapy for unilateral localised prostate cancer","volume":"125","author":"Langley","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.02.003_b0235","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00345-023-04352-9","article-title":"Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected","volume":"41","author":"Duwe","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0240","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1089\/end.2006.20.688","article-title":"Focal prostate cryoablation: initial results show cancer control and potency preservation","volume":"20","author":"Bahn","year":"2006","journal-title":"J Endourol"},{"key":"10.1016\/j.euo.2025.02.003_b0245","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(12)70121-3","article-title":"Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0250","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","article-title":"Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study","volume":"68","author":"Ahmed","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0255","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.1002\/cam4.5692","article-title":"Cryotherapy for partial gland ablation of prostate cancer: oncologic and safety outcomes","volume":"12","author":"Aker","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2025.02.003_b0260","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/ans.15526","article-title":"Magnetic resonance image\u2010guided focal laser ablation in clinically localized prostate cancer: safety and efficacy","volume":"89","author":"Al-Hakeem","year":"2019","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.euo.2025.02.003_b0265","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.juro.2014.03.033","article-title":"Targeted focal therapy for the management of organ confined prostate cancer","volume":"192","author":"Barqawi","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0270","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.urology.2021.03.054","article-title":"5-Year outcomes following focal laser ablation of prostate cancer","volume":"155","author":"Chao","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.02.003_b0275","first-page":"825","article-title":"HIFU focal therapy for prostate cancer using intraoperatory contrast enhanced ultrasound","volume":"72","author":"Claros","year":"2019","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0280","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1148\/radiol.2019181987","article-title":"Image-guided irreversible electroporation of localized prostate cancer: functional and oncologic outcomes","volume":"292","author":"Collettini","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2025.02.003_b0285","doi-asserted-by":"crossref","first-page":"172","DOI":"10.23736\/S2724-6051.22.04853-4","article-title":"MRI\/real-time ultrasound image fusion guided high-intensity focused ultrasound: a prospective comparative and functional analysis of different ablative techniques","volume":"75","author":"De Luca","year":"2023","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.euo.2025.02.003_b0290","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/bju.12370","article-title":"Focal cryoablation: a treatment option for unilateral low\u2010risk prostate cancer","volume":"113","author":"Durand","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.02.003_b0295","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2022.01.005","article-title":"Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience","volume":"81","author":"Reddy","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0300","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1016\/j.prro.2020.12.005","article-title":"Focal brachytherapy for localized prostate cancer: midterm outcomes","volume":"11","author":"Ta","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0305","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.eururo.2015.04.029","article-title":"Complications, recovery, and early functional outcomes and oncologic control following in-bore focal laser ablation of prostate cancer","volume":"68","author":"Lepor","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0310","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/pcan.2015.47","article-title":"Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control","volume":"19","author":"Ting","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.02.003_b0315","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/JU.0000000000001133","article-title":"Hemigland cryoablation of clinically significant prostate cancer: intermediate-term followup via magnetic resonance imaging guided biopsy","volume":"204","author":"Chuang","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0320","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.euo.2018.03.011","article-title":"Two-year outcomes following focal laser ablation of localized prostate cancer","volume":"1","author":"Chao","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0325","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0330","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.euo.2019.04.008","article-title":"Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort","volume":"3","author":"Blazevski","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0335","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.urolonc.2018.05.022","article-title":"Prostate cancer treatment by the latest focal HIFU device with MRI\/TRUS-fusion control biopsies: a prospective evaluation","volume":"36","author":"Von Hardenberg","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0340","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clgc.2022.06.009","article-title":"Focal high-intensity focused ultrasound vs. active surveillance for ISUP grade 1 prostate cancer: medium-term results of a matched-pair comparison","volume":"20","author":"Marra","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.02.003_b0345","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bju.12816","article-title":"Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST 11\u2010vascular\u2010targeted photodynamic (VTP) therapy","volume":"116","author":"Moore","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.02.003_b0350","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/JU.0000000000000506","article-title":"Focal therapy for localized prostate cancer with either high intensity focused ultrasound or cryoablation: a single institution experience","volume":"203","author":"Tourinho-Barbosa","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0355","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bju.15004","article-title":"Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry","volume":"125","author":"Lovegrove","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.02.003_b0360","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3390\/cancers15102727","article-title":"Salvage radical prostatectomy after primary focal ablative therapy: a systematic review and meta-analysis","volume":"15","author":"Blank","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.02.003_b0365","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0370","doi-asserted-by":"crossref","unstructured":"Bangma C, Doan P, Zhu L, et al. Has active surveillance for prostate cancer become safer? Lessons learned from a global clinical registry. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.07.003.","DOI":"10.1016\/j.euo.2024.07.003"},{"key":"10.1016\/j.euo.2025.02.003_b0375","doi-asserted-by":"crossref","first-page":"781.e17","DOI":"10.1016\/j.urolonc.2021.01.027","article-title":"Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: recommendations of an international Delphi consensus","volume":"39","author":"Tan","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.02.003_b0380","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/bju.14369","article-title":"Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems","volume":"122","author":"Pompe","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.02.003_b0385","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300018","article-title":"Patient-reported outcomes 12 years after localized prostate cancer treatment","volume":"2","author":"Donovan","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euo.2025.02.003_b0390","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.02.003_b0395","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(16)30592-X","article-title":"Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study","volume":"388","author":"Yaxley","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.02.003_b0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bju.16207","article-title":"Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy","volume":"133","author":"Geboers","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.02.003_b0405","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature","volume":"68","author":"F\u00fctterer","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.02.003_b0410","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41391-023-00699-7","article-title":"Oncological results and cancer control definition in focal therapy for prostate cancer: a systematic review","volume":"27","author":"Nicoletti","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.02.003_b0415","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41391-023-00698-8","article-title":"Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)","volume":"27","author":"Nicoletti","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.02.003_b0420","doi-asserted-by":"crossref","unstructured":"Tay KJ, Fong KY, Stabile A, et al. Established focal therapy\u2014HIFU, IRE, or cryotherapy\u2014where are we now?\u2014A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. In press. https:\/\/doi.org\/10.1038\/s41391-024-00911-2.","DOI":"10.1038\/s41391-024-00911-2"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:39:27Z","timestamp":1778143167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125000392"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.02.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Focal Therapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}